Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma.

Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Tabouret E, Mokhtari K, Figarella-Branger D, Rousseau A, Procaccio V.

Neuro Oncol. 2019 Apr 26. pii: noz072. doi: 10.1093/neuonc/noz072. [Epub ahead of print] No abstract available.

PMID:
31095694
2.

Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma.

Boisselier B, Dugay F, Belaud-Rotureau MA, Coutolleau A, Garcion E, Menei P, Guardiola P, Rousseau A.

Oncotarget. 2018 Nov 13;9(89):36017-36028. doi: 10.18632/oncotarget.26330. eCollection 2018 Nov 13.

3.

Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Bruno A, Labreche K, Daniau M, Boisselier B, Gauchotte G, Royer-Perron L, Rahimian A, Lemoine F, de la Grange P, Guégan J, Bielle F, Polivka M, Adam C, Meyronet D, Figarella-Branger D, Villa C, Chrétien F, Eimer S, Davi F, Rousseau A, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K, Alentorn A.

Neuro Oncol. 2018 Jul 5;20(8):1092-1100. doi: 10.1093/neuonc/noy019.

4.

Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases.

El Ayoubi R, Boisselier B, Rousseau A.

J Neurooncol. 2017 Sep;134(2):465-467. doi: 10.1007/s11060-017-2523-8. Epub 2017 Jun 6. No abstract available.

PMID:
28589424
5.

Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma.

Boisselier B, De Carli E, Rousseau A.

J Neurooncol. 2017 May;133(1):217-219. doi: 10.1007/s11060-017-2432-x. Epub 2017 Apr 18. No abstract available.

PMID:
28421462
6.

BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.

Breton Q, Plouhinec H, Prunier-Mirebeau D, Boisselier B, Michalak S, Menei P, Rousseau A.

Brain Behav. 2017 Feb 10;7(3):e00641. doi: 10.1002/brb3.641. eCollection 2017 Mar.

7.

Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas.

Labussière M, Rahimian A, Giry M, Boisselier B, Schmitt Y, Polivka M, Mokhtari K, Delattre JY, Idbaih A, Labreche K, Alentorn A, Sanson M.

Oncologist. 2016 Sep;21(9):1131-5. doi: 10.1634/theoncologist.2016-0003. Epub 2016 Jul 8.

8.

Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases.

Uguen A, Laurent C, Samaison L, Boisselier B, Talagas M, Costa S, Aziza J, Mokhtari K, Le Maréchal C, Marcorelles P.

Hum Pathol. 2015 Aug;46(8):1189-96. doi: 10.1016/j.humpath.2015.04.013. Epub 2015 May 13.

PMID:
26037215
9.

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, Marie Y, Bruno A, Boisselier B, Giry M, Savatovsky J, Touat M, Belaid H, Kamoun A, Idbaih A, Houillier C, Luo FR, Soria JC, Tabernero J, Eoli M, Paterra R, Yip S, Petrecca K, Chan JA, Finocchiaro G, Lasorella A, Sanson M, Iavarone A.

Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.

10.

VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.

Di Stefano AL, Labussiere M, Lombardi G, Eoli M, Bianchessi D, Pasqualetti F, Farina P, Cuzzubbo S, Gallego-Perez-Larraya J, Boisselier B, Ducray F, Cheneau C, Moglia A, Finocchiaro G, Marie Y, Rahimian A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M.

J Neurooncol. 2015 Feb;121(3):499-504. doi: 10.1007/s11060-014-1677-x. Epub 2014 Dec 7.

PMID:
25488073
11.

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M.

Br J Cancer. 2014 Nov 11;111(10):2024-32. doi: 10.1038/bjc.2014.538. Epub 2014 Oct 14.

12.

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.

Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M.

Neurology. 2014 Sep 23;83(13):1200-6. doi: 10.1212/WNL.0000000000000814. Epub 2014 Aug 22.

PMID:
25150284
13.

Mutational analysis of primary central nervous system lymphoma.

Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K.

Oncotarget. 2014 Jul 15;5(13):5065-75.

14.

A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.

Catteau A, Girardi H, Monville F, Poggionovo C, Carpentier S, Frayssinet V, Voss J, Jenkins R, Boisselier B, Mokhtari K, Sanson M, Peyro-Saint-Paul H, Giannini C.

Acta Neuropathol Commun. 2014 Jun 2;2:58. doi: 10.1186/2051-5960-2-58.

15.

IDH mutations: genotype-phenotype correlation and prognostic impact.

Wang XW, Ciccarino P, Rossetto M, Boisselier B, Marie Y, Desestret V, Gleize V, Mokhtari K, Sanson M, Labussière M.

Biomed Res Int. 2014;2014:540236. doi: 10.1155/2014/540236. Epub 2014 Apr 30.

16.

Tumor and endothelial cell hybrids participate in glioblastoma vasculature.

El Hallani S, Colin C, El Houfi Y, Idbaih A, Boisselier B, Marie Y, Ravassard P, Labussière M, Mokhtari K, Thomas JL, Delattre JY, Eichmann A, Sanson M.

Biomed Res Int. 2014;2014:827327. doi: 10.1155/2014/827327. Epub 2014 Apr 24.

17.

An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.

Laffaire J, Di Stefano AL, Chinot O, Idbaih A, Gallego Perez-Larraya J, Marie Y, Vintonenko N, Boisselier B, Farina P, Delattre JY, Figarella-Branger D, Honnorat J, Sanson M, Ducray F.

Biomed Res Int. 2014;2014:282815. doi: 10.1155/2014/282815. Epub 2014 Apr 2.

18.

Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Alentorn A, van Thuijl HF, Marie Y, Alshehhi H, Carpentier C, Boisselier B, Laigle-Donadey F, Mokhtari K, Scheinin I, Wesseling P, Ylstra B, Capelle L, Hoang-Xuan K, Sanson M, Delattre JY, Reijneveld JC, Idbaih A.

Neuro Oncol. 2014 Mar;16(3):400-8. doi: 10.1093/neuonc/not227. Epub 2013 Dec 12.

19.

Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapy.

Ducray F, Kaloshi G, Houillier C, Idbaih A, Ribba B, Psimaras D, Marie Y, Boisselier B, Alentorn A, Dainese L, Navarro S, Mokhtari K, Sanson M, Hoang-Xuan K, Delattre JY.

J Neurooncol. 2013 Nov;115(2):261-5. doi: 10.1007/s11060-013-1224-1. Epub 2013 Aug 17.

PMID:
23955572
20.

Deciphering the 8q24.21 association for glioma.

Enciso-Mora V, Hosking FJ, Kinnersley B, Wang Y, Shete S, Zelenika D, Broderick P, Idbaih A, Delattre JY, Hoang-Xuan K, Marie Y, Di Stefano AL, Labussière M, Dobbins S, Boisselier B, Ciccarino P, Rossetto M, Armstrong G, Liu Y, Gousias K, Schramm J, Lau C, Hepworth SJ, Strauch K, Müller-Nurasyid M, Schreiber S, Franke A, Moebus S, Eisele L, Forsti A, Hemminki K, Tomlinson IP, Swerdlow A, Lathrop M, Simon M, Bondy M, Sanson M, Houlston RS.

Hum Mol Genet. 2013 Jun 1;22(11):2293-302. doi: 10.1093/hmg/ddt063. Epub 2013 Feb 11.

21.

Interlaboratory comparison of IDH mutation detection.

van den Bent MJ, Hartmann C, Preusser M, Ströbel T, Dubbink HJ, Kros JM, von Deimling A, Boisselier B, Sanson M, Halling KC, Diefes KL, Aldape K, Giannini C.

J Neurooncol. 2013 Apr;112(2):173-8. doi: 10.1007/s11060-013-1056-z. Epub 2013 Jan 29.

PMID:
23358936
22.

Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.

Wang XW, Boisselier B, Rossetto M, Marie Y, Idbaih A, Mokhtari K, Gousias K, Hoang-Xuan K, Delattre JY, Simon M, Labussière M, Sanson M.

Cancer. 2013 Feb 15;119(4):806-13. doi: 10.1002/cncr.27798. Epub 2012 Nov 26.

23.

Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

Di Stefano AL, Enciso-Mora V, Marie Y, Desestret V, Labussière M, Boisselier B, Mokhtari K, Idbaih A, Hoang-Xuan K, Delattre JY, Houlston RS, Sanson M.

Neuro Oncol. 2013 May;15(5):542-7. doi: 10.1093/neuonc/nos284. Epub 2012 Nov 16.

24.

Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussière M, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2012 Nov;14(11):1393-403. doi: 10.1093/neuonc/nos217. Epub 2012 Oct 16. Erratum in: Neuro Oncol. 2013 Mar;15(3):403.

25.

Detection of IDH1 mutation in the plasma of patients with glioma.

Boisselier B, Gállego Pérez-Larraya J, Rossetto M, Labussière M, Ciccarino P, Marie Y, Delattre JY, Sanson M.

Neurology. 2012 Oct 16;79(16):1693-8. doi: 10.1212/WNL.0b013e31826e9b0a. Epub 2012 Oct 3.

PMID:
23035067
26.

Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M, Adam C, Figarella-Branger D, Miquel C, Vital A, Ghesquières H, Gressin R, Delwail V, Taillandier L, Chinot O, Soubeyran P, Gyan E, Choquet S, Houillier C, Soussain C, Tanguy ML, Marie Y, Mokhtari K, Hoang-Xuan K.

Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.

27.

The renal v-ATPase a4 subunit is expressed in specific subtypes of human gliomas.

Gleize V, Boisselier B, Marie Y, Poëa-Guyon S, Sanson M, Morel N.

Glia. 2012 May;60(6):1004-12. doi: 10.1002/glia.22332. Epub 2012 Mar 27.

PMID:
22460948
28.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Epub 2011 Aug 31. Review.

PMID:
21885076
29.

Chromosome 7p11.2 (EGFR) variation influences glioma risk.

Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y, Enciso-Mora V, Idbaih A, Delattre JY, Hoang-Xuan K, Marie Y, Boisselier B, Carpentier C, Wang XW, Di Stefano AL, Labussière M, Gousias K, Schramm J, Boland A, Lechner D, Gut I, Armstrong G, Liu Y, Yu R, Lau C, Di Bernardo MC, Robertson LB, Muir K, Hepworth S, Swerdlow A, Schoemaker MJ, Wichmann HE, Müller M, Schreiber S, Franke A, Moebus S, Eisele L, Försti A, Hemminki K, Lathrop M, Bondy M, Houlston RS, Simon M.

Hum Mol Genet. 2011 Jul 15;20(14):2897-904. doi: 10.1093/hmg/ddr192. Epub 2011 Apr 29.

30.

Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.

Desestret V, Ciccarino P, Ducray F, Crinière E, Boisselier B, Labussière M, Polivka M, Idbaih A, Kaloshi G, von Deimling A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M.

J Neurooncol. 2011 Nov;105(2):219-24. doi: 10.1007/s11060-011-0587-4. Epub 2011 Apr 24.

PMID:
21516462
31.

Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target.

Bikeye SN, Colin C, Marie Y, Vampouille R, Ravassard P, Rousseau A, Boisselier B, Idbaih A, Calvo CF, Leuraud P, Lassalle M, El Hallani S, Delattre JY, Sanson M.

Cancer Cell Int. 2011 Apr 15;11:10. doi: 10.1186/1475-2867-11-10. No abstract available.

32.

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.

Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D.

Acta Neuropathol. 2010 Dec;120(6):719-29. doi: 10.1007/s00401-010-0777-8. Epub 2010 Nov 16.

PMID:
21080178
33.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
34.

COLD PCR HRM: a highly sensitive detection method for IDH1 mutations.

Boisselier B, Marie Y, Labussière M, Ciccarino P, Desestret V, Wang X, Capelle L, Delattre JY, Sanson M.

Hum Mutat. 2010 Dec;31(12):1360-5. doi: 10.1002/humu.21365. Epub 2010 Nov 9.

PMID:
20886613
35.

Genetic risk profiles identify different molecular etiologies for glioma.

Simon M, Hosking FJ, Marie Y, Gousias K, Boisselier B, Carpentier C, Schramm J, Mokhtari K, Hoang-Xuan K, Idbaih A, Delattre JY, Lathrop M, Robertson LB, Houlston RS, Sanson M.

Clin Cancer Res. 2010 Nov 1;16(21):5252-9. doi: 10.1158/1078-0432.CCR-10-1502. Epub 2010 Sep 16.

36.

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Crinière E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2010 Jun 8;74(23):1886-90. doi: 10.1212/WNL.0b013e3181e1cf3a. Epub 2010 Apr 28.

PMID:
20427748
37.

A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.

El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A, Delattre JY, Maniotis AJ, Sanson M.

Brain. 2010 Apr;133(Pt 4):973-82. doi: 10.1093/brain/awq044.

38.

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target.

Bikeye SN, Colin C, Marie Y, Vampouille R, Ravassard P, Rousseau A, Boisselier B, Idbaih A, Calvo CF, Leuraud P, Lassalle M, El Hallani S, Delattre JY, Sanson M.

Cancer Cell Int. 2010 Jan 11;10:1. doi: 10.1186/1475-2867-10-1.

39.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.

PMID:
19636000
40.

Genome-wide association study identifies five susceptibility loci for glioma.

Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idbaih A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau C, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS.

Nat Genet. 2009 Aug;41(8):899-904. doi: 10.1038/ng.407. Epub 2009 Jul 5.

41.

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.

Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Crinière E, Carvalho Silva R, Laigle-Donadey F, Rousseau A, Mokhtari K, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY.

Neuropathol Appl Neurobiol. 2009 Apr;35(2):208-13. doi: 10.1111/j.1365-2990.2008.00977.x.

PMID:
19284481
42.

No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis.

Boisselier B, Marie Y, El Hallani S, Kaloshi G, Iershov A, Kavsan V, Psimaras D, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.

J Neurooncol. 2009 Sep;94(2):169-72. doi: 10.1007/s11060-009-9817-4. Epub 2009 Mar 3.

PMID:
19255724
43.

TP53 codon 72 polymorphism is associated with age at onset of glioblastoma.

El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodéro M, Chinot O, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2009 Jan 27;72(4):332-6. doi: 10.1212/01.wnl.0000341277.74885.ec.

PMID:
19171829
44.

NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas.

Benetkiewicz M, Idbaih A, Cousin PY, Boisselier B, Marie Y, Crinière E, Hoang-Xuan K, Delattre JY, Sanson M, Delattre O.

PLoS One. 2009;4(1):e4107. doi: 10.1371/journal.pone.0004107. Epub 2009 Jan 1.

45.

TP53 mutations but no CHEK2 *1100DelC variant in familial gliomas.

El Hallani S, Boisselier B, Marie Y, Paris S, Idbaih A, Carpentier C, Hoang-Xuan K, Delattre JY, Sanson M.

Cancer Genet Cytogenet. 2009 Jan 15;188(2):126-8. doi: 10.1016/j.cancergencyto.2008.10.006. No abstract available.

PMID:
19100519
46.

Genomic changes in progression of low-grade gliomas.

Idbaih A, Carvalho Silva R, Crinière E, Marie Y, Carpentier C, Boisselier B, Taillibert S, Rousseau A, Mokhtari K, Ducray F, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY.

J Neurooncol. 2008 Nov;90(2):133-40. doi: 10.1007/s11060-008-9644-z. Epub 2008 Jul 11.

PMID:
18618226
47.

Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Idbaih A, Crinière E, Marie Y, Rousseau A, Mokhtari K, Kujas M, El Houfi Y, Carpentier C, Paris S, Boisselier B, Laigle-Donadey F, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2008 Aug;10(4):540-7. doi: 10.1215/15228517-2008-022. Epub 2008 Jun 10.

48.

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.

Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18.

PMID:
18262501
49.

Mutational analysis of Rac2 in gliomas.

Idbaih A, Paris S, Boisselier B, Marie Y, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY.

J Neurooncol. 2008 May;87(3):365-6. doi: 10.1007/s11060-008-9521-9. Epub 2008 Jan 24. No abstract available.

PMID:
18217210
50.

TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY.

Cancer Genet Cytogenet. 2007 Sep;177(2):103-7.

PMID:
17854663

Supplemental Content

Loading ...
Support Center